Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone + Henagliflozin Initial Combination Therapy in Diabetic Kidney Disease with Microalbuminuria
ChiCTR2300078226Phase 4Recruiting
- Sponsor
- Peking University First Hospital
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of finerenone, henagliflozin and losartan in type 2 diabetes mellitus (T2DM) and diabetic glomerulosclerosis (3 arms), sponsored by Peking University First Hospital. Primary endpoint: Urinary microalbumin creatinine ratio (UACR). Started Nov 2023; status: recruiting.
02
Drugs
finerenonehenagliflozinlosartan
03
Conditions
type 2 diabetes mellitus (T2DM)diabetic glomerulosclerosis
Beyond the preview
Go deeper on ChiCTR2300078226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078226.